Q32 Bio Inc. Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing therapies for alopecia areata (AA) and other autoimmune diseases. The company's lead asset is bempikibart (ADX-914), an anti-IL-7Rα antibody currently in Phase 2 clinical trials. The company operates as a single segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7.6) million | $(11.0) million |
| Operating Expenses | $7.7 million | $12.2 million |
| Cash and Cash Equivalents | $50.8 million | $65.5 million |
| Total Debt (Venture) | $8.2 million | $9.7 million |
| Stockholders' Equity | $46.3 million | $(4.0) million |
Note: The company has no product revenue. Other income for Q1 2026 was $0.1 million, primarily interest income.
Material Changes vs. Prior Period
- Reduced Burn Rate: Net loss decreased by $3.4 million (31%) compared to Q1 2025. Total operating expenses declined by $4.5 million, driven by a $3.9 million reduction in R&D expenses and a $0.6 million reduction in G&A expenses.
- R&D Restructuring: R&D spend dropped significantly due to the sale of the ADX-097 asset to Akebia Therapeutics in November 2025 (eliminating related costs) and lower headcount following a February 2025 restructuring.
- Equity Position: Stockholders' equity improved from a deficit of $4.0 million in Q1 2025 to a positive $46.3 million in Q1 2026. This was primarily due to the derecognition of a $55.0 million refund liability related to the Horizon/Amgen collaboration termination, resolved via an equity grant in November 2025.
- Financing Activity: The company raised $10.4 million in net proceeds from a Registered Direct Offering in February 2026. Subsequent to the quarter end, an additional $13.8 million was raised via an At-The-Market (ATM) program.
Guidance, Outlook, and Risks
- Clinical Progress: The company expects to report 36-week topline data from the SIGNAL-AA Part B Phase 2 trial in mid-2026. Enrollment for this trial was completed in October 2025.
- Liquidity Outlook: Management projects that existing cash ($50.8 million), combined with subsequent ATM proceeds and guaranteed milestones from the ADX-097 sale, will fund operations into the first half of 2028.
- Capital Needs: The company expects to incur significant losses for the foreseeable future and will require substantial additional capital to complete development and commercialization.
- Key Risks:
- Development Risk: Dependence on the success of bempikibart; clinical trials may fail or be delayed.
- Regulatory Risk: Uncertainty regarding FDA approval timelines and potential changes in regulatory policy.
- Third-Party Reliance: Dependence on CROs and CDMOs, including potential impacts from the BIOSECURE Act on Chinese vendors (e.g., WuXi Biologics).
- Intellectual Property: Reliance on licensed IP from Bristol-Myers Squibb (BMS); failure to meet diligence obligations could result in termination.
Investor Verification Checklist
- Verify the timeline and data readout expectations for the SIGNAL-AA Part B Phase 2 trial (expected mid-2026).
- Confirm the status of the ATM offering program and the total capital raised subsequent to March 31, 2026.
- Review the terms of the BMS License Agreement regarding diligence milestones and potential termination risks.
- Assess the impact of the BIOSECURE Act on the company's supply chain, specifically regarding reliance on WuXi Biologics or other designated entities.
- Monitor the company's cash burn rate against the projected runway into the first half of 2028.